NIH deputy director leaving

Deputy Director Raynard Kington is leaving the National Institutes of Health (NIH) this summer after 10 years with the agency to take a position as president of Grinnell College in Iowa. Raynard KingtonImage: Wikimedia commons, NIH"I have a lump in my throat imagining Raynard leaving the NIH, where he has made so many outstanding and long-lasting contributions," Collins wrote in linkurl:a statement announcing Kington's resignation;http://www.nih.gov/about/director/02172010_statement_kington.ht

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Deputy Director Raynard Kington is leaving the National Institutes of Health (NIH) this summer after 10 years with the agency to take a position as president of Grinnell College in Iowa.
Raynard Kington
Image: Wikimedia commons,
NIH
"I have a lump in my throat imagining Raynard leaving the NIH, where he has made so many outstanding and long-lasting contributions," Collins wrote in linkurl:a statement announcing Kington's resignation;http://www.nih.gov/about/director/02172010_statement_kington.htm yesterday. "Personally, I could not ask for a better Deputy Director, who has guided me on so many critical issues since last August. His counsel has been invaluable." Kingston is a PhD physician who served as the NIH's director of the Office of Behavioral and Social Sciences Research, acting director of the National Institute on Alcohol Abuse and Alcoholism, and the principal deputy director of the NIH. In addition, he took the role of acting director between Elias Zerhouni's resignation in October 2008 and Francis Collins' appointment last August, during which time he participated in distributing the $10.4 million increase in the NIH's budget as part of the economic stimulus package and implementing the regulatory changes issued by President Obama's Executive Order regarding human embryonic stem cell research. "He performed each of these roles splendidly, always going far beyond the call of duty," Collins said in the statement. Collins called Kington an "unsung hero" of the agency. "Many aren't even aware of the innumerable battles he fought on behalf of our agency, on behalf of our staff, and in defense of science," Collins wrote. "Raynard's modest and self-effacing manner belies a lion-hearted champion of the NIH mission."
**__Related stories:__***linkurl:NIH loosens stem cell consent rules;http://www.the-scientist.com/blog/display/55814/
[6th July 2009]*linkurl:New NIH head talks budget, priorities;http://www.the-scientist.com/blog/display/55179/
[10th November 2008]*linkurl:New NIH deputy;http://www.the-scientist.com/article/display/21033/
[21st January 2003]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development